Pharmasset was acquired by Gilead in 2011 for $11 billion for their oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset was acquired by Gilead in 2011 for $11 billion for their oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).